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Abstract 
Introduction: Quality of life (QoL) is an important outcome in chronic kidney disease (CKD). 
Patients feel symptoms are an important determinant of QoL. However, this relation is 
unknown. The aims of this study were to investigate the impact of the number and severity of 
symptoms on quality of life in elderly pre-dialysis patients, assessed by both the effect of 
symptoms and their importance relative to kidney function, and other clinical variables on 
QoL. 
Methods: The EQUAL Study is an ongoing European prospective follow-up study in late 
stage 4/5 CKD patients aged ≥65 years. We used patients included between March 2012 
and December 2015. Patients scored their symptoms with the Dialysis Symptom Index, and 
QoL with the RAND-36 item Health Survey (RAND-36). The RAND-36 results in a physical 
component summary (PCS) and a mental component summary (MCS). We used linear 
regression to estimate the relation between symptoms and QoL at baseline and after six 
months, and to calculate the variance in QoL explained by symptoms. 
Results: 1079 (73%) patients had a baseline questionnaire (median age 75, 66% male, 98% 
Caucasian) and 627 (42%) patients a follow- up questionnaire. At baseline, every additional 
symptom changed MCS with -0.81 (95% CI -0.91;-0.71), and PCS with -0.50 (95% CI-0.62;-
0.39). In univariable analyses number of symptoms explained 22% of MCS variance and 
11% of PCS variance, whereas eGFR only explained 1%. 
Conclusions: In elderly CKD stage 4/5 patients symptoms have a substantial impact on 
QoL. This indicates symptoms should have a more prominent role in clinical decision 
making.  
Keywords: clinical epidemiology, CKD, pre-dialysis, quality of  life, symptoms 
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Introduction 
Elderly patients with advanced chronic kidney disease (CKD) often have a poor quality of life 
(QoL).[1, 2] This is an important outcome in these patients since it predicts mortality and 
morbidity.[3-5] Although many definitions of QoL exist, it is commonly defined as “the 
functional effect of an illness and its consequent therapy upon a patient, as perceived by the 
patient” which is determined by an individual’s capacity to cope and to adapt.[6, 7]  
In CKD patients clinical variables are considered important determinants for QoL.[8-12] 
However, kidney function, the most important biological factor in CKD and determinant for 
many treatment choices, does not influence QoL as much as expected. [12, 13] Although 
Pagels et al. and Chin et al. found a difference in QoL between patients with moderately 
severe versus severe CKD, no linear effect of eGFR on QoL has been observed.[12, 13] A 
possible explanation for this can be found in the conceptual model by Wilson et al. which 
portrays QoL as the result of a chain of consecutive elements, passing from biological 
variables through symptom status through functional status to QoL.[14] From this model it 
could be inferred that factors earlier in the chain – affecting QoL through more intermediate 
variables – will have a weaker effect. The effect of biological factors, such as kidney 
function, is mediated by symptoms, which may thus be more important in determining QoL. 
The IDEAL study, where a large part of the CKD patients initiated dialysis based on 
symptoms instead of planned kidney function, illustrates this idea.[15] 
CKD patients suffer from a wide range of physical and psychological symptoms. They can 
range from tiredness and itching to feeling anxious or irritable. Patients consider symptoms 
as one of the most important aspects of their disease, and both patients and nephrologists 
believe symptoms should be one of the main focuses in CKD research.[16-18]  Nonetheless, 
research on symptoms and their effect on QoL in pre-dialysis patients is limited.[19, 20] A 
few notable exceptions suggest that an increase in symptoms is associated with a decrease 
in QoL. De Goeij et al. found an increase in symptoms over time accompanied by a 
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decrease in QoL in 436 pre-dialysis patients.[1] In a cross-sectional study by Abdel-Kader et 
al. symptoms were negatively correlated with QoL in 87 CKD stage 4/5 patients.[11] 
This study aimed to fill this knowledge gap by investigating the impact of number and 
severity of symptoms on quality of life in pre-dialysis patients, assessed by both the effect of 
symptoms and their importance relative to kidney function and other clinical variables. In this 
study the word effect is used to investigate the relation between symptoms and QoL, an 
etiological research aim. The term relative importance is used when investigating the part of 
QoL that is determined by symptoms, a research aim more at the edge of etiological 
research.    
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Methods 
Study design and population 
The European Quality study on when to start dialysis (EQUAL study) is an ongoing 
prospective cohort study in advanced CKD patients in six European countries: Germany, 
Italy, Poland, Sweden, The Netherlands and the United Kingdom. We included patients of 65 
years and older with an eGFR that had dropped to 20 ml/min/1.73m2 or lower for the first 
time during the last six months in patients referred to a nephrologist. Patients were eligible 
when they were followed in a nephrology clinic, but were excluded if the drop in eGFR 
resulted from an acute event, or if the patient had received any form of renal replacement 
therapy (RRT) in the past. Patients were followed until kidney transplantation, death, refusal 
for further participation, moving to a center not participating in the EQUAL study, loss to 
follow-up, or end of follow-up. For the current study end of follow-up was determined at the 
29th of November 2016 and patients were censored when starting dialysis. A full description 
of the study has been published elsewhere.[21]  
For our analyses we used the baseline and six months follow-up data of the patients who 
were recruited for the EQUAL study between March 2012 and December 2015 and filled in 
at least the QoL part of the patient questionnaire at baseline. The study was approved by the 
medical ethics committee or institutional review boards (as appropriate) of all participating 
centers. Written informed consent was obtained from all patients. 
Data collection   
The EQUAL study followed patients receiving routine medical care as provided by the 
nephrology clinic. Data were collected and entered into a web-based clinical record form that 
was developed for this specific purpose. The information included patients’ demographics, 
ethnicity, kidney disease, comorbid conditions, diet and medication, physical examination, 
and laboratory data.  
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The eGFR was calculated using the 4-variable Modification of Diet in Renal Disease 
(MDRD) formula, taking into account age, sex, race, and serum creatinine.[22] Primary 
kidney disease was classified by the treating nephrologist according to the codes of the 
European Renal Association-European Dialysis and Transplantation Association.[23] We 
grouped patients into four classes of primary kidney disease: glomerulonephritis, diabetes 
mellitus, renal vascular disease, and other kidney diseases. Educational level was classified 
into low (no education or primary school only), intermediate (primary and secondary school), 
and high (academic education). 
All laboratory investigations and physical examinations were performed through standard 
protocols and procedures according to routine care at the local participating sites. In order to 
standardize these data, all participating centers completed a questionnaire to capture details 
on local laboratory methods, units of measurement and normal ranges. All data were then 
recalculated into one uniform unit of choice.  
Additionally, data regarding the patient’s lifestyle, marital status, QoL, as well as the 
presence and severity of uraemic symptoms were obtained via self-administered paper 
patient questionnaires. The list of uraemic symptoms was based on the Dialysis Symptom 
Index, which consists of 30 symptoms, and was complemented with the items bleeding, loss 
of weight, and loss of strength.[24] The patients had to score the presence of these 
symptoms over the past month. For each symptom experienced, patients subsequently rated 
how much they had been bothered by that symptom using a 5-point Likert scale with the 
options “not at all”, “a little bit”, ”somewhat”, ”quite a bit”, or “very much”. The total number of 
symptoms resulted in a score that ranged from 0 to 33. The reported symptom severity was 
summarized in a score that ranged from 0 to 165 by counting the Likert scale points. 
Unreported symptoms were assigned a severity score of zero.[11] 
QoL was measured with the RAND-36, a 36 item questionnaire measuring QoL on eight 
dimensions, resulting in an overall physical component score (PCS) and mental component 
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score (MCS). The eight dimensions are physical functioning, role limitations due to physical 
problems, bodily pain, social functioning, role limitations due to emotional problems, mental 
health, general health and vitality. To score a dimension at least half of the items in that 
dimension had to be completed.[25] The PCS and MCS were calculated using norm based 
scoring, which employs linear transformation to achieve standardized scores with a mean of 
50 and a standard deviation of 10 for each dimension by using the United States (US) 
population as a reference group.[26] Research has shown using the United States reference 
group is as good as using a Dutch reference group.[26] 
Statistical analysis 
Baseline characteristics were presented as mean ± standard deviation (SD) for normally 
distributed continuous variables, skewed continuous variables as median with interquartile 
range (IQR), and categorical variables as percentages.  
Multiple imputation was used to minimize the risk of bias.[27] Missing values of number of 
symptoms, and symptom severity at baseline and after six months, as well as potential 
confounders at baseline were imputed (using 10 repetitions).  
We conducted linear regression analyses to estimate the effect of number and severity of 
symptoms on the outcomes PCS and MCS. This was performed both at baseline and after 
six months of follow-up. All residuals were plotted to check the linearity assumption. To 
check the direction of the effect of symptoms on QoL we estimated the effect of baseline 
determinants on six months QoL, adjusted for baseline QoL using a linear regression 
analysis. Next, the effect of the difference in symptoms between baseline and six months of 
follow-up (delta symptoms) on the difference in QoL between baseline and six months of 
follow-up (delta QoL) was estimated with linear regression. All analyses were adjusted for 
the potential confounders: age, sex, ethnicity, country of residence, educational level, 
diabetes mellitus, cerebrovascular disease, myocardial infarction, hypertension, malignancy, 
psychiatric disease, body mass index, primary kidney disease, albumin and eGFR. All 
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analyses including only baseline variables were performed in patients with a QoL patient 
questionnaire at baseline. Analyses including baseline and six months follow-up variables 
were performed in patients with a QoL patient questionnaire at baseline and after six months 
of follow-up. To simplify clinical interpretation we have added the effects of number and 
severity of symptoms on PCS and MCS per quartile, using the interquartile range for number 
and severity of symptoms. 
Lastly, we calculated the impact of symptoms on QoL using linear regression analysis to 
calculate the explained variance as a measure of importance. In this analysis we defined 
different variable clusters: demographics (sex, age, ethnicity, education level, country of 
residence), comorbidities (diabetes mellitus, cardiovascular disease, myocardial infarction, 
malignancy, psychiatric disease) and primary kidney disease, eGFR, other laboratory 
measurements (albumin, hemoglobin, proteinuria), symptom number, and symptom severity. 
These clusters were included both separately with a univariable analysis and stepwise with a 
multivariable analysis. This way, the impact of each of these variables as well as their 
additive effect could be calculated. In addition to the estimated associations, this analysis 
gives more clinical context and demonstrates the relative importance of different 
determinants of QoL. The explained variance was calculated at baseline, after six months, 
and for change in symptoms and change in QoL. 
To test the robustness of the results we performed several sensitivity analyses. First, we 
stratified all analyses by sex, since the occurrence of symptoms as well as the perceived 
QoL might differ between men and women and thereby affect the associations between 
symptoms and QoL. Second, we repeated all analyses without using multiple imputation for 
missing values. Third, we repeated all analyses only using multiple imputation for baseline 
confounders, not for symptom number or severity. Fourth, we repeated the linear regression 
analysis at baseline only including patients with a patient questionnaire at baseline and after 
6 months of follow-up. Finally, we calculated the explained variance without the symptoms 
fatigue, feeling sad, feeling nervous, and feeling anxious since these are both symptoms and 
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part of the SF-36 and thereby might influence the explained variance. P-values <0.05 were 
considered statistically significant. All analyses were performed using SPSS version 23.0 for 
Windows. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Patient characteristics 
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Of the 1486 patients in EQUAL by the 31th of December 2015, 1079 (73%) filled in the QoL 
part of the baseline patient questionnaire and 627 (42%) filled in the QoL part of the patient 
questionnaire at baseline and after six months of follow-up. Missing symptom number and 
symptom severity were imputed. Of the 452 patients missing QoL at 6 months of follow-up, 
40 already started dialysis, 61 died, 29 withdrew from the study, 7 received a kidney 
transplantation, and 3 patients had not yet reached the 6 months follow-up measurement. 
The other 312 (29%) patients were defined as non-responders. Patients with complete 
follow-up had a median age of 76 (IQR 70-80), 65% were male, and 98% were Caucasian 
(table 1). Sixty-four percent of these patients were married or living together, 28% had a low 
education level, 48% an intermediate education level, and 21% a high education level. 
Hypertension was present in 90%, a malignancy in 22%, and a psychiatric disease in 6% of 
these patients. In the 1079 patients with a baseline questionnaire these numbers were 
virtually the same. Supplemental table 1 shows the baseline characteristics for the 312 
patients where follow-up questionnaires were missing. 
Table 2 shows the number of symptoms, symptom severity, MCS, and PCS at baseline and 
after six months of follow-up for complete cases. The numbers showed only small changes 
over the first six months. In figure 1 the prevalence of symptoms with the severity score per 
symptom at baseline are shown. The most prevalent symptoms at baseline were fatigue, a 
decreased interest in sex, and loss of strength. “A decreased interest in sex” and “difficulty 
becoming sexually aroused” were the symptoms that scored the most “very much bother” as 
symptom severity score. After six months (figure 2) the most prevalent symptoms and the 
most severe symptoms remained unchanged. 
The effect of symptoms on QoL  
Table 3 shows the association between symptoms and QoL at baseline. With every 
additional symptom the MCS changed with -0.81 (95% CI -0.91 to -0.71) and the PCS with -
0.50 (95% CI -0.62 to -0.39). The association between symptom severity and MCS was -
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0.23 (95% CI -0.26 to -0.20) and -0.18 (95% CI -0.21 to -0.15) for PCS. After six months 
results were similar (results not shown). Table 4 shows the effect of symptom number and 
severity on QoL over time. After adjustment, one extra symptom at baseline changed MCS 
at six months of follow-up with -0.42 (95% CI -0.59 to -0.25), and PCS with -0.15 (95% CI -
0.24 to -0.05). With every point increase in symptom severity at baseline the change in MCS 
at six months of follow-up was -0.14 (95% CI -0.19 to -0.09), and for PCS this was -0.05 
(95% CI -0.07 to -0.02). Table 5 shows the association between the change in symptom 
number and severity during the first six months of follow-up and the change in QoL during 
those six months. The association was -0.51 (-0.71 to -0.31) for symptom number and MCS, 
-0.22 (-0.36 to -0.08) for symptom number and PCS, -0.18 (-0.25 to -0.12) for symptom 
severity and MCS, and -0.09 (-0.14 to -0.04) for symptom severity and PCS. All negative 
numbers indicate a decrease in QoL. 
Although these effect sizes seem quite small, they are clinically relevant effects. This is 
illustrated by the changes in QoL per quartile of symptom number and symptom severity.  
For example, the change from quartile one to quartile three for symptom number and MCS 
at baseline is over 8 points (Supplemental table 7, 8 and 9).  
  
The importance of symptoms in explaining QoL 
Tables 6a and 6b show the R2 for the different variable clusters that influence QoL, both 
separately and stepwise at baseline. In the univariable analysis symptom number and 
severity have an R2 of 0.22 and 0.21 for MCS respectively, while eGFR has an R2 of 0.01 
and the other variables have a maximum R2 of 0.02. For PCS the R2 for symptom number 
and severity is smaller, 0.11 and 0.16, and demographic variables also explain a large part 
of the variance with an R2 of 0.12. The R2 for eGFR is again 0.01. When adding the 
variables stepwise in a multivariable analysis for MCS, symptom number significantly adds 
to the R2 in addition to demographic and clinical variables, increasing the R2 from 0.06 to 
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0.26. Symptom severity does not add more to this correlation. For PCS, the contribution of 
symptoms is smaller but also substantial. The R2 increased from 0.17 to 0.24 with symptom 
number and up to 0.28 with symptom severity. In contrast, eGFR did not add to the R2 in 
multivariable analyses, neither for MCS nor for PCS. Both after six months and for change 
between baseline and six months of follow-up symptom number and severity remained the 
variables with the largest R2 in univariable analyses and contributed most to the R2 in 
multivariable analyses. In these analyses eGFR did not contribute to the R2 either. 
Sensitivity analyses 
Stratifying by sex showed a higher number and severity of symptoms and a lower QoL in 
women compared to men (supplemental table 2). The effect of symptoms on QoL did not 
show large differences between the different sexes (supplemental table 3, 4, 5). Repeating 
the analyses without multiple imputation showed similar results, as did the analyses when 
only using multiple imputation for baseline confounders. Repeating the baseline linear 
regression analysis with only the 627 patients who had a QoL questionnaire at baseline and 
after six months of follow-up showed no substantial differences in the results (supplemental 
table 6). Removing symptoms that are also part of the SF-36 changed the R2 to 0.17 
(symptom number)  and 0.16 (symptom severity) in the univariable analysis for MCS at 
baseline. For PCS the R2 changed to 0.12 and 0.18 in the univariable analysis. In the 
multivariable analysis the R2 changed to 0.19 (symptom number) and 0.21 (symptom 
severity) for MCS, and to 0.25 and 0.29 for PCS. 
 
 
Discussion 
In this cohort of 1079 incident elderly pre-dialysis patients we found a wide range of 
symptom occurrence and severity. Most prevalent symptoms were fatigue, a decreased 
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interest in sex, and loss of strength. Symptoms on sexuality scored highest on severity. Both 
an increase in number of symptoms and in symptom severity were associated with a 
decrease in QoL. In addition, baseline symptoms were related to QoL after six months of 
follow-up. The impact of symptoms on QoL is substantial, especially compared to eGFR 
which did not impact MCS or PCS at all.  
Overall, effects on MCS were larger as compared with effects on PCS. We hypothesize this 
might be due to depressive symptoms having more impact on mental QoL as compared with 
physical QoL, due to the fact that a part of these symptoms are heavily reflected in MCS 
questions, while the other symptoms do not have that much overlap with PCS questions. 
The sensitivity analysis in which the explained variance is calculated without overlapping 
symptoms seems to support this hypothesis. However, the analyses show only small 
changes as compared with the analyses including these overlapping symptoms.   
The difference in impact on QoL between symptoms and eGFR we found supports the 
conceptual model by Wilson et al. showing symptoms are a more determinant for QoL.[14] 
With this knowledge on symptom impact, a more prominent role for symptoms in clinical 
decision making in the pre-dialysis phase seems justifiable. That this is already happening 
has been illustrated by IDEAL, where symptoms overruled eGFR on the decision when to 
start RRT.[15] As far as we know there is no other research on the impact of symptoms on 
QoL in pre-dialysis patients. 
Our results on the number of symptoms and symptom severity are in line with existing 
research in CKD patients.[17, 28-30] Almutary et al. performed a systematic review 
investigating symptom burden in CKD stage 4 and 5. They found seven studies on symptom 
burden in pre-dialysis patients. These studies showed a wide range of symptoms, with 
fatigue being the most common symptom, followed by pruritus and dry skin. Pre-dialysis 
patients had more psychological problems compared to patients on dialysis. The average 
number of symptoms ranged from 6 to 20, compared to 13 in our population.[17] Other 
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research in 436 CKD patients of which 24.5% were in the pre-dialysis phase (mean age 52, 
55% male), showed an average symptom number of 13 with fatigue and pain as most 
common symptoms. In this study “difficulty becoming sexually aroused” and “decreased 
interest in sex” were two of the most severe symptoms when experienced, which is in 
concordance with our study.[28]  
Yong et al. performed a study in 179 end stage renal disease patients of which 45 were 
treated conservatively (mean age 73), looking both at symptom burden and at its relation to 
QoL. They found a negative correlation between symptom burden and QoL, which is similar 
to our study, although the CKD stage in this population differs from our population.[31] In a 
study by Abdel-Kader et al. symptom burden was negatively correlated with MCS but not 
with PCS, while symptom severity was negatively correlated with both MCS and PCS in 87 
CKD stage 4/5 patients.[11] The lack of correlation between symptom burden and PCS in 
the latter study could be explained by the small population or by the lack of correction for 
confounding. 
There is only one other study we know of that looks at symptoms and QoL over time.[1] De 
Goeij et al. studied this relation in 436 pre-dialysis patients (median age 69, 66% male, 
mean eGFR 16.9ml/min/1.73 m2). They found an increase in symptoms over time, and a 
decrease in QoL (both MCS and PCS). However, they did not directly assess the relation 
between symptoms and QoL over time. Although de Goeij et al. studied a longer period of 
time, their findings on symptoms and QoL are quite similar to our results. 
The main strength of this study is the size of the study population. As far as we know this is 
the largest population of pre-dialysis patients in which the relation between symptoms and 
quality of life has been evaluated. Another strength is the inclusion of incident pre-dialysis 
patients (who for the first time passed a pre-specified eGFR level), which decreased the risk 
of survival bias. In addition, the exclusion criteria for EQUAL are minimal, ensuring a wide 
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range of elderly pre-dialysis patients were included, making the results generalizable to the 
clinical practice of pre-dialysis care for elderly patients. 
 
The main limitation of this study is the duration of follow-up. In the future follow-up will be 
extended to at least four years, but for this study only the first six months of follow-up were 
available. Although this is a limitation, it is one of the first studies researching symptoms and 
QoL over time and thereby still an important contribution to the body of evidence on this 
subject. A second limitation is the number of non-responders  after six months of follow-up. 
Due to this problem we had to restrict the number of patients in analyses involving the six 
months follow-up measurement. Another limitation is the use of the Dialysis Symptom Index 
as symptom questionnaire. This symptom questionnaire was developed and validated in 
dialysis patients. Since patient’s follow-up continues during dialysis this questionnaire is a 
good choice for the entire EQUAL study. For this particular study in pre-dialysis patients the 
lack of validation in this group is a limitation. However, the Dialysis Symptom Index has been 
used in pre-dialysis populations before, with valid results.[32, 33] Finally, based on the 
model of Wilson which implies symptoms result in QoL, and on the measurements over time 
which gave us the opportunity to measure symptoms at an earlier moment compared to 
QoL, we interpreted our results as effects. However, we would like to emphasize the caution 
needed when interpreting our results as causal, and the possibility of methodological 
limitations, such as residual confounding, which could make causal interpretation very 
difficult.  
 
In conclusion, this study showed an effect of symptoms on QoL, and quantified their relative 
importance. The prevalence and severity of symptoms in our population emphasizes the 
need for attention on symptoms during outpatient clinic visits. The effect of symptoms on a 
clinically relevant outcome measure indicates symptoms should have a more prominent role 
in clinical decision making and guidelines in CKD should emphasize this. Opportunities for 
future research include studying the impact of individual symptoms on QoL and testing 
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whether interventions on symptoms improve QoL, as well as studying the sub-scales of the 
RAND-36 to identify which sub-scales could be best aimed at when trying to improve QoL. 
Future results of the EQUAL study on the start of dialysis will give the opportunity to 
investigate the role of symptoms in that period more thoroughly.  
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Table 1. Baseline characteristics in patients with a patient questionnaire at baseline (n=1079) and in 
patients with a patient questionnaire at baseline and follow-up (n=627) 
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 QoL questionnaire 
at baseline, n=1079 
QoL questionnaire both at 
baseline and 6 months, n=627 
Sex, male 66 65 
Age, years 75 (70-80) 76 (70-80) 
Ethnicity   
Caucasian 98 98 
Black 1 1 
Other 1 1 
Primary Kidney Disease   
Glomerular disease 10 9 
Tubulo-interstitial disease 9 10 
Diabetes Mellitus 20 18 
Hypertension 35 37 
Other/ unknown 28 26 
Education a   
Low 30 28 
Intermediate 48 48 
High 17 21 
Other 3 3 
Marital status, married or living together 64 64 
Diabetes Mellitus, yes b 40 37 
Hypertension, yes c 89 90 
Cerebrovascular Disease, yes  15 15 
Myocardial Infarction, yes 18 17 
Malignancy, yes 21 22 
Psychiatric disease, yes 7 6 
Body Mass Index, kg/m² 28 (25-31) 29 (25-31) 
Index eGFR, ml/min/1.73m² d 17.1 (3.1) 17.4 (2.7) 
eGFR baseline, ml/min/1.73m² d 19.0 (5.5) 19.7 (5.3) 
Serum albumin, g/L 37.6 (5.8) 37.7 (5.4) 
Hemoglobin, mmol/L 7.2 (1.0) 7.3 (1.0) 
Proteinuria, g/24h 1.9 (0.6-6.3) 1.6 (0.5-4.9) 
Values are given as a percentage, means (±SD) or median (IQR). 
Missings: baseline group; marital status 15, education 14, proteinuria 852, albumin 101, BMI 63, 
hemoglobin 12; baseline and six months group: marital status 9, proteinuria 517, albumin 56 BMI 32, 
hemoglobin 7 a Defined as: low, no education or primary school only; intermediate, primary and 
secondary school; high, academic education. ᵇ Defined as the presence of diabetes mellitus as 
primary kidney disease or a history of diabetes mellitus.  c Defined as either the presence of 
hypertension as primary kidney disease or a history of hypertension. d eGFR was calculated using the 
4-variable Modification of Diet in Renal Disease (MDRD) formula. Index eGFR; eGFR at time of study 
inclusion, eGFR baseline; eGFR at baseline measurement.  
QoL: Quality of life 
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Table 2. Symptom and QoL descriptives at baseline and after 6 months  
 QoL questionnaire 
at baseline, n=1079 
QoL questionnaire both at baseline and 6 
months, n=627 
  
 Baseline Baseline  6 months Scale Example 
Symptom number 12.6 (6.5) 
n=819 
12.4 (6.2) 
n=460 
13.5 (7.2) 
n=460 
0-33 In the past month have you experienced any of the  
following symptoms? Muscle cramps; yes/no 
Symptom severity 33 (18 to 51) 
n=720 
33 (19 to 48) 
n=407 
36 (19 to 57) 
n=407 
0-165 In the past month have you experienced any of the  
following symptoms? If yes, how much did it bother you? Not at 
all/a little bit/ somewhat/ quite a bit/ very much 
MCS 50.3 (10.9) 
n=1079 
50.6 (10.4) 
n=627 
48.3 (11.7) 
n=627 
50 (10)* During the past 4 weeks, have you had any of the  
following problems with your work or other regular activities as 
a result of any emotional problems (such as  
feeling depressed or anxious)? 
PCS 34.8 (12.1) 
n=1079 
35.1 (11.4) 
n=627 
36.5 (9.8) 
n=627 
50 (10)* During the past 4 weeks, have you had any of the  
following problems with your work or other  
regular activities as a result of your physical health? 
Values are given as means ± SD or median (interquartile range) 
*standardized score mean (standard deviation) 
QoL; quality of life, MCS; Mental Component Summary, PCS: Physical Component Summary  
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Table 3. Effect size per point increase of symptom number and severity on MCS and PCS at baseline 
(n=1079) 
 MCS  PCS  
Symptom number, 
crude 
-0.80 (-0.90 to -0.70) -0.64 (-0.76 to -0.53) 
Symptom number, 
adjusted* 
-0.81 (-0.91 to -0.71) -0.50 (-0.62 to -0.39) 
Symptom severity, 
crude 
-0.22 (-0.25 to -0.19) -0.22 (-0.25 to -0.19) 
Symptom severity, 
adjusted* 
-0.23 (-0.26 to -0.20) -0.18 (-0.21 to -0.15) 
*Adjusted for: age, sex, ethnicity, country of residence, educational level, diabetes mellitus, 
cerebrovascular disease, myocardial infarction, hypertension, malignancy, psychiatric disease, BMI, 
primary kidney disease,albumin, eGFR.  
MCS; Mental Component Summary, PCS: Physical Component Summary 
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Table 4. Effect size per point increase in symptom number and severity on MCS and PCS six month 
changes (n=627) 
 M6 MCS  M6 PCS  
Baseline symptom 
number, crude* 
-0.42 (-0.58 to -0.26) -0.16 (-0.26 to -0.06) 
Baseline symptom 
number, adjusted** 
-0.42 (-0.59 to -0.25) -0.15 (-0.24 to -0.05) 
Baseline symptom 
severity, crude* 
-0.13 (-0.18 to -0.09) -0.05 (-0.08 to -0.02) 
Baseline symptom 
severity, adjusted** 
-0.14 (-0.19 to -0.09) -0.05 (-0.07 to -0.02) 
*Adjusted for: baseline QoL 
**Adjusted for: baseline QoL, age, sex, ethnicity, country of residence, educational level, diabetes 
mellitus, cerebrovascular disease, myocardial infarction, hypertension, malignancy, psychiatric 
disease, BMI, primary kidney disease, albumin, eGFR.  
MCS; Mental Component Summary, PCS: Physical Component Summary, QoL; Quality of Life 
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Table 5. Linear regression; effect size of change in symptom number and severity on change in MCS 
and PCS (n=627) 
 Change in MCS  Change in PCS  
Change in symptom 
number, crude 
-0.48 (-0.67 to -0.29) -0.22 (-0.35 to -0.09) 
Change in symptom 
number, adjusted 
-0.51 (-0.71 to -0.31) -0.22 (-0.36 to -0.08) 
Change in symptom 
severity, crude 
-0.18 (-0.24 to -0.11) -0.09 (-0.14 to -0.05) 
Change in symptom 
severity, adjusted 
-0.18 (-0.25 to -0.12) -0.09 (-0.14 to -0.04) 
Adjusted for: age, sex, ethnicity, country of residence, educational level, diabetes mellitus, 
cerebrovascular disease, myocardial infarction, hypertension, malignancy, psychiatric disease, BMI, 
primary kidney disease, albumin, eGFR.  
MCS; Mental Component Summary, PCS: Physical Component Summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26 
 
Table 6a. Explained variance for MCS and PCS, for the separate variable clusters (n=1079) 
 R2 MCS R2 PCS 
Demographics 0.02 0.12 
Comorbidities+ PKD 0.02 0.04 
eGFR 0.01 0.01 
Other lab measurements 0.02 0.01 
Symptom number 0.22 0.11 
Symptom severity 0.21 0.16 
Demographics: sex, age, ethnicity, education level, country of residence 
Comorbidities + PKD: diabetes mellitus, cerebrovascular disease, myocardial infarction, malignancy, 
psychiatric disease, primary kidney disease 
Other laboratory measurements: albumin, hemoglobin, proteinuria 
MCS; Mental Component Summary, PCS: Physical Component Summary 
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Table 6b. Explained variance for MCS and PCS, for the stepwise combined variable clusters (n=1079) 
 R2 MCS R2 PCS 
1.Demographics 0.02 0.12 
2. 1+Comorbidities+ PKD 0.04 0.16 
3. 2+ eGFR 0.04 0.16 
4. 3+Other lab measurements 0.06 0.17 
5. 4+symptom number 0.26 0.24 
6. 5+symptom severity 0.26 0.28 
Demographics: sex, age, ethnicity, education level, country of residence. 
Comorbidities + PKD: diabetes mellitus, cerebrovascular disease, myocardial infarction, malignancy, 
psychiatric disease, primary kidney disease 
Other laboratory measurements: albumin, hemoglobin, proteinuria. 
DM; diabetes mellitus, CVD; cardiovascular disease, MI; myocardial infarction, PKD; primary kidney 
disease 
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Legend to figures 
Figure 1. Symptom prevalence and scoring according to 5 Likert scale at baseline (n=1079) 
Figure 2. Symptom prevalence and scoring according to 5 Likert scale at six months follow-up 
(n=627) 
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Figure 1. Symptom prevalence and scoring according to 5 Likert scale at baseline (n=1079) 
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Figure 2. Symptom prevalence and scoring according to 5 Likert scale at six months follow-up 
(n=627) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
